News
New research highlights significant insurance-driven hurdles, increasing second-line uptake of Fabhalta (Novartis), and strong physician interest in pipeline therapies including zaltenibart (Omeros), ...
11d
Dealbreaker on MSNVor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in FundingVor Bio is licensing global rights a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder ...
Alexion to present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at EAN 2025: Cambridge, UK Monday, June 23, 2025, 13:00 Hrs [IST] ...
Biologics revolutionize generalized myasthenia gravis care with fast-acting, patient-friendly therapies and a robust global pipeline redefining outcomes. The gMG treatment era is shifting rapidly-from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results